Acadia Pharmaceuticals (ACAD)

Executive Summary

Acadia Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for underserved central nervous system (CNS) disorders and rare diseases. Its lead product, Nuplazid (pimavanserin), is the first and only FDA-approved treatment for Parkinson's disease psychosis, addressing a significant unmet need. Despite facing patent challenges and competition, Nuplazid continues to generate steady revenue, providing a foundation for the company's pipeline expansion. Acadia is leveraging its expertise in serotonergic signaling to advance pimavanserin into additional indications, including a Phase 2 trial for autism spectrum disorder (ASD) and a Phase 2 study for intermittent explosive disorder (IED). The ASD trial is fully enrolled, with top-line data expected in late 2026, representing a potential near-term catalyst. Additionally, the company is exploring pimavanserin in other neuropsychiatric conditions. With a commercial-stage asset and a pipeline targeting large markets, Acadia presents a risk-reward profile balanced by approved product revenue and pipeline upside.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Data for Pimavanserin in Autism Spectrum Disorder50% success
• TBDRegulatory Update or Label Expansion for Nuplazid in Schizophrenia30% success
• 2027Phase 2 Interim or Final Data for Pimavanserin in Intermittent Explosive Disorder40% success